Related Experiment Video
Updated: Jul 17, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
Oral calorie supplements for cystic fibrosis
1University of Liverpool, Institute of Child Health, Alder Hey Children's Hospital, Eaton Road, Liverpool, Merseyside, UK, L12 2AP. r.l.smyth@liv.ac.uk
Background:
Poor nutrition occurs frequently in people with cystic fibrosis (CF) and is associated with other adverse outcomes. Oral calorie supplements are used to increase total daily calorie intake and improve weight gain. However, they are expensive and there are concerns they may reduce the amount of food eaten and not improve overall energy intake.
Objectives:
To establish whether in people with CF, oral calorie supplements: increase daily calorie intake; and improve overall nutritional intake, nutritional indices, lung function, survival and quality of life. To assess adverse effects associated with using these supplements.
Search Strategy:
We searched the Cochrane CF Trials Register comprising references from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. We contacted companies marketing oral calorie supplements. Last search: October 2006.
Selection Criteria:
Randomised or quasi-randomised controlled trials comparing use of oral calorie supplements for at least one month to increase calorie intake with no specific intervention or additional nutritional advice in people with CF.
Data Collection And Analysis:
We independently selected the included trials, assessed methodological quality and extracted data. We contacted the authors of included trials and for two trials obtained additional information.
Main Results:
Eighteen trials were identified and three, reporting results from 131 participants, were included. There were no significant differences between people receiving supplements or dietary advice alone for change in weight, height, body mass index, z score or other indices of nutrition or growth. Changes in weight (kg) at three, six and twelve months respectively were: WMD 0.32 (95% CI -0.09 to 0.72); WMD 0.47 (95% CI -0.07 to 1.02 ); and WMD 0.16 (-0.68 to 1.00). Total calorie intake was greater in people taking supplements at 12 months, WMD 265.70 (95% CI 42.94 to 488.46). There were no significant differences between the groups for anthropometric measures of body composition, lung function, gastrointestinal adverse effects or activity levels.
Authors' Conclusions:
Oral calorie supplements do not confer any additional benefit in the nutritional management of moderately malnourished children with CF over and above the use of dietary advice and monitoring alone. While nutritional supplements may be used, they should not be regarded as essential. Further randomised controlled trials are needed to establish the role of oral protein energy supplements for the short-term in people with CF and acute weight loss and also for the long-term nutritional management of adults with CF or advanced lung disease, or both.
More Related Videos
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
07:38Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome
Published on: August 3, 2021
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Drugs for Treatment of Constipation-Predominant IBS
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube through...
Chronic Pancreatitis II: Collaborative Care
Assessment: